Publication

Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue

Journal Paper/Review - Oct 19, 1998

Units
PubMed

Citation
Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel R. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. The Journal of experimental medicine 1998; 188:1493-501.
Type
Journal Paper/Review (English)
Journal
The Journal of experimental medicine 1998; 188
Publication Date
Oct 19, 1998
Issn Print
0022-1007
Pages
1493-501
Brief description/objective

Activation of autoreactive T cells can lead to autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM). The initiation and maintenance of IDDM by dendritic cells (DC), the most potent professional antigen-presenting cells, were investigated in transgenic mice expressing the lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) under the control of the rat insulin promoter (RIP-GP mice). We show that after adoptive transfer of DC constitutively expressing the immunodominant cytotoxic T lymphocyte (CTL) epitope of the LCMV-GP, RIP-GP mice developed autoimmune diabetes. Kinetic and functional studies of DC-activated CTL revealed that development of IDDM was dependent on dose and timing of antigenic stimulation. Strikingly, repeated CTL activation by DC led to severe destructive mononuclear infiltration of the pancreatic islets but also to de novo formation of islet-associated organized lymphoid structures in the pancreatic parenchyma. In addition, repetitive DC immunization induced IDDM with lymphoid neogenesis also in perforin-deficient RIP-GP mice, illustrating that CD8(+) T cell-dependent inflammatory mechanisms independent of perforin could induce IDDM. Thus, DC presenting self-antigens not only are potent inducers of autoreactive T cells, but also help to maintain a peripheral immune response locally; therefore, the induction of autoimmunity against previously ignored autoantigens represents a potential hazard, particularly in DC-based antitumor therapies.